ArticleJACC. Case reports2025
Advances in Hybrid Management Strategies for Arrhythmogenic Cardiomyopathy Progression in an Amateur Athlete.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lead-mediated ventricular tachycardia and lead-mediated radiofrequency energy delivery: Innovative LEADHeartRhythm case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArrhythmogenic cardiomyopathy (ACM) is a rare inherited disorder leading to ventricular arrhythmias and sudden cardiac death. CASE SUMMARY: A middle-aged male amateur cyclist with ventricular arrhythmias complicated by myocardial infarction with non-obstructive coronary arteries during fast ventricular tachycardias recurrence underwent a successful endocardial ablation, resulting in a prolonged arrhythmia-free period. ACM was suspected, although its diagnostic criteria were not met at that time. In 2024, ventricular tachycardia recurred, prompting multidisciplinary re-evaluation. Hybrid epicardial mapping and cryoablation resulted in complete acute noninducibility of VT. The patient has remained arrhythmia-free for over 9 months. DISCUSSION: This case highlights the evolving nature of ACM and the benefits of hybrid epicardial ablation techniques. The novel cryoablation system offers precise lesion creation, especially in challenging anatomical locations. TAKE-HOME MESSAGES: Dynamic reassessment and personalized, multidisciplinary management are crucial in ACM. In complex cases, hybrid imaging, epicardial mapping, myocardial biopsy, and cryoablation may enhance patient safety and treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.